Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers

NCT04019743 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypertension
Dyslipidemias

Interventions

DRUG: CKD-330 16/10mg Tab. 1T and D086 Tab. 1T
DRUG: CKD-333 16/10/40mg formulation 1 Tab. 1T
DRUG: CKD-333 16/10/40mg formulation 2 Tab. 1T

Sponsor

Chong Kun Dang Pharmaceutical